可能因为您的浏览器不支持样式,您可以更新您的浏览器到最新版本,以获取对此功能的支持,访问下面的网站,获取关于浏览器的信息:
[1] Bonnardeaux A, Davies E, Jeunemaitre X, et al. AngiotensinⅡ type Ⅰ receptor gene polymorphisms in human essential hypertension [J] . Hypertension, 1994, 24:63-69.
[2] Katsuya T, Koite G, Yee TW, et al. Association of angiotensiogen T235 variant with increased risk of coronary heart disease [J] . Lancet, 1995, 345:1600-1603.
[3] Furuta H, Deng-Fu Guo, Inagami T. Molecular cloning and sequending of hegene encoding human angiotensinⅡ type 1 receptor [J] . Biochem Biophys Res Commun, 1992, 28:17-26.
[4] VanGeel PP, Pinto YM, Voors AA, et al. AngiotensinⅡ typeⅠ receptor A1166C polymorphism is associated with an increased response to angiotensinⅡ in human arteries [J] . Hypertension, 2000, 35:717-721.
[5] Carluccio M, Soccio M, DeCaterina R, et al.Aspects of gene polymorphismsin cardiovascular diseases: the renin-angiogensin system [J] . Eur J Clin Invest, 2001, 31:1-14.
[6] Tiert L, Bonnardeaux A, Poirier O, et al. Synergisitic effects of angiotensin converting enzyme and angiotensin Ⅱ tyep 1 receptor gene plymorphisms on risk of myocardial infarction [J] . Lancet, 1994, 344:910-913.
[7] Petes S, Gotting B, Trummel M, et al. Valsartan for prevention of restenosis after stenting of type B2/C lesions: the VALPREST trial[J] . J Invasive Cardial, 2001, 13(2):93-97.